Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Are biosimilars as efficacious as their reference drugs?

Paul Cornes • 22 Jun 2017
EHA 2017
Leukemia

Paul Cornes, MD, from the University Hospital Bristol NHS Foundation Trust, Bristol, UK, talks to us about biosimilars and whether they are suitable as a cheaper alternative to current reference drugs. He explains the concern with biosimilars, namely in their switching over from reference drugs in cancer treatment, due to the possibility of them possessing different antibody profiles. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Paul Cornes

4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes • 22 Jun 2017
1:21
Explaining biosimilars to our patients
Paul Cornes • 27 Jun 2017
3:56
Can the dream of affordable cancer care come true?
Paul Cornes • 21 Mar 2017
2:43
Why do we need biosimilars?
Paul Cornes • 21 Mar 2017

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals